Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens

Erica N. Parker, Bryon S. Drown, Emily J. Geddes, Hyang Yeon Lee, Nahed Ismail, Gee W. Lau, Paul J. Hergenrother

Research output: Contribution to journalLetter

Abstract

Gram-negative bacterial infections are a significant public health concern, and the lack of new drug classes for these pathogens is linked to the inability of most drug leads to accumulate inside Gram-negative bacteria1–7. Here, we report the development of a web application—eNTRyway—that predicts compound accumulation (in Escherichia coli) from its structure. In conjunction with structure–activity relationships and X-ray data, eNTRyway was utilized to re-design Debio-1452—a Gram-positive-only antibiotic8—into versions that accumulate in E. coli and possess antibacterial activity against high-priority Gram-negative pathogens. The lead compound Debio-1452-NH3 operates as an antibiotic via the same mechanism as Debio-1452, namely potent inhibition of the enoyl-acyl carrier protein reductase FabI, as validated by in vitro enzyme assays and the generation of bacterial isolates with spontaneous target mutations. Debio-1452-NH3 is well tolerated in vivo, reduces bacterial burden in mice and rescues mice from lethal infections with clinical isolates of Acinetobacter baumannii, Klebsiella pneumoniae and E. coli. This work provides tools for the facile discovery and development of high-accumulating compounds in E. coli, and a general blueprint for the conversion of Gram-positive-only compounds into broad-spectrum antibiotics.

Original languageEnglish (US)
JournalNature Microbiology
DOIs
StatePublished - Nov 18 2019

Fingerprint

Escherichia coli
Gram-Negative Bacterial Infections
Acyl Carrier Protein
Anti-Bacterial Agents
Acinetobacter baumannii
Klebsiella pneumoniae
Enzyme Assays
Pharmaceutical Preparations
Oxidoreductases
Public Health
X-Rays
Mutation
Infection
Lead
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology
  • Genetics
  • Microbiology (medical)
  • Cell Biology

Cite this

Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens. / Parker, Erica N.; Drown, Bryon S.; Geddes, Emily J.; Lee, Hyang Yeon; Ismail, Nahed; Lau, Gee W.; Hergenrother, Paul J.

In: Nature Microbiology, 18.11.2019.

Research output: Contribution to journalLetter

@article{c2eb9e0b86db4b04b5008946ea2d1710,
title = "Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens",
abstract = "Gram-negative bacterial infections are a significant public health concern, and the lack of new drug classes for these pathogens is linked to the inability of most drug leads to accumulate inside Gram-negative bacteria1–7. Here, we report the development of a web application—eNTRyway—that predicts compound accumulation (in Escherichia coli) from its structure. In conjunction with structure–activity relationships and X-ray data, eNTRyway was utilized to re-design Debio-1452—a Gram-positive-only antibiotic8—into versions that accumulate in E. coli and possess antibacterial activity against high-priority Gram-negative pathogens. The lead compound Debio-1452-NH3 operates as an antibiotic via the same mechanism as Debio-1452, namely potent inhibition of the enoyl-acyl carrier protein reductase FabI, as validated by in vitro enzyme assays and the generation of bacterial isolates with spontaneous target mutations. Debio-1452-NH3 is well tolerated in vivo, reduces bacterial burden in mice and rescues mice from lethal infections with clinical isolates of Acinetobacter baumannii, Klebsiella pneumoniae and E. coli. This work provides tools for the facile discovery and development of high-accumulating compounds in E. coli, and a general blueprint for the conversion of Gram-positive-only compounds into broad-spectrum antibiotics.",
author = "Parker, {Erica N.} and Drown, {Bryon S.} and Geddes, {Emily J.} and Lee, {Hyang Yeon} and Nahed Ismail and Lau, {Gee W.} and Hergenrother, {Paul J.}",
year = "2019",
month = "11",
day = "18",
doi = "10.1038/s41564-019-0604-5",
language = "English (US)",
journal = "Nature Microbiology",
issn = "2058-5276",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens

AU - Parker, Erica N.

AU - Drown, Bryon S.

AU - Geddes, Emily J.

AU - Lee, Hyang Yeon

AU - Ismail, Nahed

AU - Lau, Gee W.

AU - Hergenrother, Paul J.

PY - 2019/11/18

Y1 - 2019/11/18

N2 - Gram-negative bacterial infections are a significant public health concern, and the lack of new drug classes for these pathogens is linked to the inability of most drug leads to accumulate inside Gram-negative bacteria1–7. Here, we report the development of a web application—eNTRyway—that predicts compound accumulation (in Escherichia coli) from its structure. In conjunction with structure–activity relationships and X-ray data, eNTRyway was utilized to re-design Debio-1452—a Gram-positive-only antibiotic8—into versions that accumulate in E. coli and possess antibacterial activity against high-priority Gram-negative pathogens. The lead compound Debio-1452-NH3 operates as an antibiotic via the same mechanism as Debio-1452, namely potent inhibition of the enoyl-acyl carrier protein reductase FabI, as validated by in vitro enzyme assays and the generation of bacterial isolates with spontaneous target mutations. Debio-1452-NH3 is well tolerated in vivo, reduces bacterial burden in mice and rescues mice from lethal infections with clinical isolates of Acinetobacter baumannii, Klebsiella pneumoniae and E. coli. This work provides tools for the facile discovery and development of high-accumulating compounds in E. coli, and a general blueprint for the conversion of Gram-positive-only compounds into broad-spectrum antibiotics.

AB - Gram-negative bacterial infections are a significant public health concern, and the lack of new drug classes for these pathogens is linked to the inability of most drug leads to accumulate inside Gram-negative bacteria1–7. Here, we report the development of a web application—eNTRyway—that predicts compound accumulation (in Escherichia coli) from its structure. In conjunction with structure–activity relationships and X-ray data, eNTRyway was utilized to re-design Debio-1452—a Gram-positive-only antibiotic8—into versions that accumulate in E. coli and possess antibacterial activity against high-priority Gram-negative pathogens. The lead compound Debio-1452-NH3 operates as an antibiotic via the same mechanism as Debio-1452, namely potent inhibition of the enoyl-acyl carrier protein reductase FabI, as validated by in vitro enzyme assays and the generation of bacterial isolates with spontaneous target mutations. Debio-1452-NH3 is well tolerated in vivo, reduces bacterial burden in mice and rescues mice from lethal infections with clinical isolates of Acinetobacter baumannii, Klebsiella pneumoniae and E. coli. This work provides tools for the facile discovery and development of high-accumulating compounds in E. coli, and a general blueprint for the conversion of Gram-positive-only compounds into broad-spectrum antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=85075334551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075334551&partnerID=8YFLogxK

U2 - 10.1038/s41564-019-0604-5

DO - 10.1038/s41564-019-0604-5

M3 - Letter

C2 - 31740764

JO - Nature Microbiology

JF - Nature Microbiology

SN - 2058-5276

ER -